TABLE 3.
Incidence of the most common adverse events in both groups.
| Tacrolimus group (n = 100) | Hydrocortisone group (n = 100) | |
|---|---|---|
| Skin burning sensation, No. (%) | 60 (60%)* | 12 (12%) |
| Skin erythema, No. (%) | 20 (20%)* | 4 (4%) |
| Skin atrophy, No. (%) | 0 (0%) | 8 (8%)* |
| Skin infection, No. (%) | 4 (4%) | 6 (6%) |
*(p ≤ 0.05) is considered significant.